Page 95 - 79_04

José
Carlos
Menéndez,
Mercedes
Villacampa

42. Gabhe,
N.;
Tasgoankar,
R.;
Dagade,
B.;
Rao,
D.;
Sawant,
P.;
Shirodkar,
A.
(2013).
Dipeptidyl

peptidase
IV
(DPP-­-IV)
inhibition:
A
novel
approach

for
the
treatment
of
type
II
diabetes

mellitus.
Int.
J.
Pharm.
Sci.
4,
629-­-637.

43. Gupta,
R.;
Walung,
S.
S.;
Tokala,
R.
K.;
Parsa,
K.
V.
L.;
Singh,
S.
K.;
Pal,
M.
(2009).
Emerging

drug
candidates
of
dipeptidyl
peptidase
IV
(DPPP-­-IV)
inhibitor
class
for
the
treatment
of

type
II
diabetes.
Curr.
Drug
Targets
10,
71-­-87.

44. Peters,
J.
W.
(2007).
11
Years
of
cyanopyrrolidines
as
DPP-­-IV
inhibitors.
Curr.
Top.
Med.

Chem.
7,
579-­-595.

45. Thoma,
R.;
Löffler,
B.;
Stihle,
M.;
Huber,
W.;
Ruf,
A.;
Hennig,
M.
(2003).
Structural
basis
of

proline-­-specific
exopeptidase
activity
as
observed
in
human
dipeptidyl
peptidase-­-IV.

Structure,
11,
947–959.

46. Nabeno,
M.;
Akahoshi,
F.;
Kishida,
H.;
Miyaguchi,
I.;
Tanaka,
Y.;
Ishii,
S.;
Kadowaki,
T.

(2013).
A
comparative
study
of
the
binding
modes
of
recently
launched
dipeptidyl

peptidase
IV
inhibitors
in
the
active
site.
Biochem.
Biophys.
Res.
Commun.
434,
191–196.

47. Grigoriadis,
D.
E.;
Hoare,
S.
R.
J.;
Lechner,
S.
M.;
Slee,
D.
H.;
Williams,
J.
A.
(2009).

Drugability
of
extracellular
targets:
discovery
of
small
molecule
drugs
targeting
allosteric,

functional,
and
subunit
-­-selective
sites
on
GPCRs
and
ion
channels.

Neuropsychopharmacology
34,
106–125.

48. Willard,
F.
S.;
Bueno,
A.
B.;
Sloop,
K.
W.
(2012).
Small
molecule
drug
discovery
at
the

Glucagon-­-Like
Peptide-­-1
receptor.
Exptl.
Diabet.
Res.,
article
ID
709893,

doi:10.1155/2012/709893.

49. He,
M.;
Guan,
N.;
Gao,
W.
W.;
Liu,
Q.;
Wu,
X.-­-Y.;
Ma,
D.
W.;
Zhong,
D.
F.;
Ge,
D.
B.;
Li,
C.;
Chen,

X.
Y.;
Yang,
L.;
Liao,
J.
Y.;
Wang,
M.
W.
(2012)
A
continued
saga
of
Boc5,
the
first
non-­-
peptidic
glucagon-­-like
peptide-­-1
receptor
agonist
with
in
vivo
activities.
Acta
Pharmacol.

Sin.
33,
148–154.

50. http://www.clinicaltrials.gov/ct2/show/NCT01676584
(consultado
el
05-­-08-­-2013).

51. Zhu,
X.;
Huang,
W.;
Qian,
H.
(2013).
GPR119
agonists:
A
novel
strategy
for
type
2
diabetes

treatment,
en
Oguntibeju,
O.
O.
Diabetes
mellitus
-­-
Insights
and
perspectives,
capítulo
4.

Intech
Open
Science.

52. Ansarullah,
L.
Y.;
Holstein,
M.;
DeRuyter,
B.;
Rabinovitch,
A.;
Guo,
Z.
(2013)
Stimulating
b-­-
Cell
regeneration
by
combining
a
GPR119
agonist
with
a
DPP-­-IV
inhibitor.
PLoS
ONE
8(1),

e53345.
doi:10.1371/journal.pone.0053345.

53. Mattei,
P.
Potent
and
selective,
orally
active
GPBAR1
agonists
as
chemical
biology
probes.

http://www.maggichurchouseevents.co.uk/bmcs/Downloads/GPCRs%20-­-
%20Tue%200905%20Mattei%20
Patrizio%20
presentation.pdf
(consultado
el
05-­-08-­-
2013).

612